Orgenesis Inc (NASDAQ: ORGS) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a "Priority Investment of Strategic National Importance."
Orgenesis Inc. (NASDAQ:ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announces that its joint venture (JV)
Goal to accelerate development, QC testing and manufacturing of Orgenesis’ cell and gene therapy platform
New assays being developed to potentially enhance the potency of cell and gene therapies for use
Orgenesis (NASDAQ:ORGS) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.23) by 147.83 percent. This is a 108.73 percent increase over losses of $(1.26) per share from the
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.